There are two major types of ocular neovascularization that affect the retina, retinal
neovascularization (NV) and subretinal or choroidal NV. Retinal NV occurs in a group of …

Age-related macular degeneration (AMD) is a common irreversible ocular disease
characterized by vision impairment among older people. Many risk factors are related to …

Age related macular degeneration (AMD) is the leading cause of vision loss of those over
the age of 65 in the industrialized world. The prevalence and need to develop effective …

Background Long-term intraocular injections of vascular endothelial growth factor (VEGF)-
neutralising proteins can preserve central vision in many patients with neovascular age …

Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove
successful in the clinic. After numerous patients with cancer or age-related macular …

Blindness, although not life threatening, is a debilitating disorder for which few, if any
treatments exist. Ocular gene therapies have the potential to profoundly improve the quality …

Background Neovascular, or wet, age-related macular degeneration causes central vision
loss and represents a major health problem in elderly people, and is currently treated with …

Background We present the results of a Phase 2a randomized controlled trial investigating
the safety, and secondary endpoints of subretinal rAAV. sFLT-1 gene therapy in patients with …

Ocular neovascularization (NV) is the primary cause of blindness in a wide range of ocular
diseases, such as diabetic retinopathy (DR) and age-related macular degeneration (AMD) …

The recent approval of voretigene neparvovec (Luxturna®) for patients with biallelic RPE65
mutation-associated inherited retinal dystrophy with viable retinal cells represents an …